louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06349135: Assessment of Serum Concentration of Interleukin-17 and Osteoprotegerin in Response to Surgical Trauma Induced by Management of Mandibular Fractures Via Intraoral Versus Extraoral Approaches: Prospective Cohort Study
Official title: Assessment of Serum Concentration of Interleukin-17 and Osteoprotegerin in Response to Surgical Trauma Induced by Management of Mandibular Fractures Via Intraoral Versus Extraoral Approaches: Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Mandibular Fractures
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-05
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with single mandibular fracture.

Brief summary: Assessment of Serum Concentration of Interleukin-17 and Osteoprotegerin in Response to Surgical Trauma Induced by Management of Mandibular Fractures via Intraoral Versus Extraoral Approaches: Prospective Cohort Study


Eligibility criteria: Inclusion Criteria:

* Single mandibular fracture.
* ORIF is done by two plates fixation with titanium plates and screws.
* Age (18-50 years).
* Recent fracture (less than 2 weeks).

Exclusion Criteria:

* Pathological fractures.
* Medical compromised patient.
* Presence of concomitant injuries.
* Patients receive radiotherapy.
* Patients receive blood transfusion.

Primary outcomes:
measure: IL-17
timeFrame: 6- weeks
measure: OPG
timeFrame: 6- weeks
Secondary outcomes:
measure: Blood Loss
timeFrame: in operation room
measure: Operative time
timeFrame: Operative time in minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06653335: Effectiveness of the Education Support Program Provided Via Text Message
Official title: EFFECTIVENESS of the EDUCATION SUPPORT PROGRAM VIA TEXT MESSAGE
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Midwifery Students
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2024-10-22
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Information will be provided to first year midwifery students via text message within the scope of the 'Basic Principles and Practice in Midwifery Education' support programme. This information is planned to last approximately 4 weeks. The study will be conducted to evaluate the effect of the information provided on the knowledge levels of the students.


Eligibility criteria: Inclusion Criteria:

* In 2023-2024 Spring Term, with the success of the Basic Principles and Practices Course in Midwifery to have completed the programme,
* Having a mobile phone,
* Accepting to participate in the research is one of the inclusion criteria of this studyc

Exclusion Criteria:

* Students who incompletely completed the post-test and first test scales will be excluded from the study.

Primary outcomes:
measure: Knowledge Measurement Questionnaire
timeFrame: Before and immediately after education
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Huang, C. S. J., Yang, S. J. H., Chiang, T. H. C., & Su, A. Y. S. (2016). Effects of Situated Mobile Learning Approach on Learning Motivation and Performance of EFL Students. Educational Technology & Society, (2016), 19 (1), 263-276.)
citation: Hardini, M. G., Khaizure, T., & Godwin, G. (2024). Exploring the Effectiveness of E-Learning in Fostering Innovation and Creative Entrepreneurship in Higher Education. Startupreneur Business Digital (SABDA Journal), 3(1), 34-42. https://doi.org/10.33050/sabda.v3i1.441
citation: Kavruk Y. (2018). Uzaktan Öğrenenlerin Kısa Mesaj ile Eğitsel Destek Sağlanmasına Yönelik Memnuniyetleri ve Öğrenme Düzeyleri. Anadolu Üniversitesi Sosyal Bilimler Enstitüsü, Yüksek Lisans Tezi. Eskişehir. 2018.
Clinical trial NCT01207635: Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
Official title: Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Cancer
Arimidex
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2010-09-23
Enrollment: 42
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Breast cancer patients receiving standard Arimidex treatment.

Brief summary: The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.

Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.


Eligibility criteria: Inclusion Criteria:

* Patient must have a history of breast cancer.
* Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
* Patient must be willing to undergo a duct lavage.
* Patient must sign an Informed Consent.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Number of Patients with Antiproliferative Effects of Arimidex
timeFrame: Study duration 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: UT MD Anderson Cancer Center
name: Banu Arun, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02940535: Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response
Official title: Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Subfertility, Female
Ovulation Disorder
Lead sponsor: Navy General Hospital, Beijing
Sponsor class: OTHER
First posted: 2016-10-21
Enrollment: 200
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The management of the poor responder patients is very difficult. Currently, there is no any standard treatment for poor responder patients. The study is designed to test a modified GnRHa protocol for poor ovarian response, low dose GnRHa early luteal phase down regulation, compare with GnRHa ultra-short protocol. This is a randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* At least two of the following three features must be present: i. Advanced maternal age (≥40 years) or any other risk factor for POR (poor ovarian response); ii. A previous POR (≤3 oocytes with a conventional stimulation protocol); iii. An abnormal ovarian reserve test (i.e. AFC \<7 follicles or AMH \<1.1 ng/ml).

Exclusion Criteria:

* Contraindications for IVF/ICSI
* Contraindications for pregnancy
* Primary ovarian insufficiency
* AFC \<3
* PGD/PGS

Primary outcomes:
measure: live birth
timeFrame: 3 years
Secondary outcomes:
measure: clinical pregnancy rate
timeFrame: 3 years
Other outcomes:
measure: multiple pregnancy
timeFrame: 3 years
measure: miscarriage
timeFrame: 3 years
measure: Ectopic pregnancy
timeFrame: 3 years
measure: Dose of HMG required
timeFrame: 3 years
measure: Duration of HMG stimulation
timeFrame: 3 years
measure: Number of oocytes retrieved
timeFrame: 3 years
measure: Number of embryos obtained
timeFrame: 3 years
measure: Number of embryos frozen
timeFrame: 3 years
measure: Adverse effects
timeFrame: 3 years
measure: Congenital Abnormalities
timeFrame: 3 years
Locations:
city: Beijing
country: China
facility: Navy General Hospital
state: Beijing
Study officials:
affiliation: Navy General Hospital, Beijing
name: Wei Shang, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Yunhai Chuai, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Mingming Shu, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Ming Zhou, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Huiming Han, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Mengnan Chen, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Navy General Hospital, Beijing
name: Lei Chen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01393535: Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery
Official title: Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiac Surgery
Keywords: Adiponectin
Prognosis
Cardiac Surgery
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2011-07-13
Enrollment: 800
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients underwent cardiac surgery in cardiovascular surgery department of xijing hospital.

Brief summary: The purpose of this study is to investigate the relationship between serum adiponectin and clinical prognosis in patients undergoing cardiac surgery.

Detailed description: Adiponectin, an adipose tissue derived protein, is an abundant protein hormone regulatory of numerous metabolic processes. Since its discovery, adiponectin has garnered considerable attention for its role in cardiovascular pathology. It has been shown to be a predictor of cardiovascular events in both the general population and patients undergoing cardiac surgery. In this study,we are planning to investigate the relationship between serum adiponectin and clinical prognosis in patients undergoing cardiac surgery.

Eligibility criteria: Inclusion Criteria:

* Patients who had underwent cardiac surgery from July 2011 to August 2012 in xijing hospital.

Exclusion Criteria:

* Nothing particular.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shannxi
Study officials:
affiliation: Xijing Hospital
name: Dinghua Yi, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01713335: Proteasis Evaluation in COPD
Official title: Proteasis Evaluation in COPD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2012-10-24
Enrollment: 134
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Stable COPD patients were recruited from pulmonary primary care of pulmonary division of CHRU of Tours.

COPD with acute exacerbation were recruited from hospitalisation of pulmonary division of CHRU of Tours and intensive care unit of CHRU of Tours.

Brief summary: The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.


Eligibility criteria: Inclusion Criteria for healthy subjects:

* Smoker with tobacco consumption of 20 pack/year
* Normal lung function tests

Exclusion Criteria for healthy subjects:

* diagnosis of lung disease during the study
* Asthma
* Lung cancer
* Pregnant and lactating women

Inclusion Criteria for stable COPD:

* Smoker with tobacco consumption of 20 pack/year
* FEV1/FVC\<70% on lung function tests
* no hospitalisation for exacerbation during 3 months before inclusion

Exclusion Criteria for stable COPD:

* Asthma
* Lung cancer
* Pregnant and lactating women

Inclusion Criteria for COPD with exacerbation:

* Smoker with tobacco consumption of 20 pack/year
* worsening of pulmonary symptoms
* FEV1/FVC\<70% on lung function tests could be obtain before or 3 months after exacerbation

Exclusion Criteria for COPD with exacerbation:

* Asthma
* Lung cancer
* Pregnant and lactating women

Primary outcomes:
measure: Kallikrein level in sputum by ELISA
timeFrame: One sample at inclusion
Secondary outcomes:
measure: Comparison between kallikrein level and clinical or functionnal parameters
timeFrame: All data will be identified at inclusion
Other outcomes:
Locations:
city: Tours
country: France
facility: CHRU Tours
Study officials:
affiliation: Service de Pneumologie, CHRU Tours, Tours, France
name: Laurent Guilleminault, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre d'Investigation Clinique, CHRU Tours, Tours, France
name: Valérie Gissot, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Service de Réanimation médicale, CHRU Tours, Tours, France
name: Antoine Guillon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06700135: Sensorimotor Stimulation on Oral Feeding
Official title: Efficacy of Sensorimotor Stimulation on Oral Feeding Skills for Neonates Post Hypoxic Ischemic Encephalopathy in Neonatal Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Neonates Post Hypoxic Ischemic Encephalopathy
Keywords: Neonates
Hypoxic ischemic encephalopathy
Sensorimotor stimulation
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-11-21
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 120
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Perinatal asphyxia and the resulting hypoxic-ischemic encephalopathy (HIE) are significant causes of irreversible adverse neurodevelopmental outcomes in children. Neonates and infants with HIE commonly experience difficulties in learning the oromotor skills of sucking, swallowing, and breathing. These feeding problems can lead to severe complications such as weight loss, dehydration, malnutrition, and developmental deficits.

Objective: The study aims to assess the efficacy of sensorimotor stimulation intervention on oral skills in neonates with post-hypoxic ischemic encephalopathy in the neonatal intensive care unit (NICU).

Methods: The study will include thirty infants with hypoxic-ischemic encephalopathy. They will be divided into two equal groups: The study group receive traditional medical treatment as well as a sensorimotor stimulation program, whereas the control group receive only traditional medical treatment


Eligibility criteria: Inclusion Criteria:

* neonates, diagnosed with post-hypoxic ischemic encephalopathy

Exclusion Criteria:

* Neonates with congenital anomalies affecting the oral-facial area,
* or syndromes associated with developmental delays,
* chronic medical complications

Primary outcomes:
measure: Transition time from tube to full oral feeding
timeFrame: - At least one-time breast feeding in a 24-hour period (Fucile et al., 2013). - Consuming eight feedings per day for two consecutive days. - Capable of consuming orally over 80% of the recommended total fluid intake within a 24-hour period (Premji et
measure: Time taken to accomplish exclusive oral feeding
timeFrame: At least one-time breast feeding in a 24-hour period (Fucile et al., 2013). - Consuming eight feedings per day for two consecutive days. - Capable of consuming orally over 80% of the recommended total fluid intake within a 24-hour period (Premji et a
Secondary outcomes:
measure: Total hospital stay
timeFrame: At least one-time breast feeding in a 24-hour period (Fucile et al., 2013). - Consuming eight feedings per day for two consecutive days. - Capable of consuming orally over 80% of the recommended total fluid intake within a 24-hour period
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05482035: Clinical Trial of Wrist Blood Pressure Monitor in Conformance With the EN ISO 81060-2:2019/A1:2020 Standard
Official title: Clinical Trial on the Effectiveness of Blood Pressure Function of Wrist Blood Pressure Monitor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Pressure
Lead sponsor: Huawei Device Co., Ltd
Sponsor class: INDUSTRY
First posted: 2022-08-01
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The accuracy and safety of wrist blood pressure (model: MLY-B10) is evaluated according to the requirement of EN ISO 81060-2:2019/A1:2020.


Eligibility criteria: Inclusion Criteria:

1. Subjects should voluntarily participate in the clinical trial and sign the informed consent form.
2. Subjects must be willing and able to follow the investigation procedures.
3. Subjects are over 18 years old whose wrist circumference should be within 13.0-20.0 cm.

Exclusion Criteria:

1. Subjects with serious arrhythmias (atrial fibrillation, atrial flutter, ventricular flutter, ventricular fibrillation, ventricular tachycardia, borderline tachycardia, sinus arrest, pathological sinus syndrome, pacemaker rhythm) showed by electrocardiogram during screening period.
2. Subject with prior allergy to nylon, fluororubber, thermoplastic polyurethane elastomer (TPU), or polyvinyl chloride (PVC) materials.
3. Subjects with prior arterial obstructive disease or arteritis.
4. Subjects who had previously undergone mastectomy.
5. Subjects with wound or wrist inflammation were measured.
6. Subjects who are receiving intravenous infusion, blood transfusion, or other catheters at the site of measurement.
7. Subjects who had eaten, drank, smoked or exercised vigorously in the 30 minutes prior to the study.
8. Subjects who have participated in other clinical trials within 30 days that may affect this trial.
9. Subjects who the investigator consider inappropriate to attend the trial.

Primary outcomes:
measure: mean difference of systolic blood pressure
timeFrame: 30 minutes
measure: mean difference of diastolic blood pressure
timeFrame: 30 minutes
measure: standard deviation of the difference of systolic blood pressure
timeFrame: 30 minutes
measure: standard deviation of the difference of diastolic blood pressure
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Shenzhen No.2 People's Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT02131935: Impaired Peripheral Endothelial Function and In-stent Restenosis
Official title: Impaired Peripheral Endothelial Function as Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Lead sponsor: Kumamoto University
Sponsor class: OTHER
First posted: 2014-05-06
Enrollment: 513
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: consecutive patient sampling This is a prospective observational study of all consecutive patients with coronary artery disease (CAD) treated with PCI at Kumamoto University Hospital between January 2010 and September 2012. Inclusion criteria consisted of patients who were symptomatic for myocardial ischemia and who were undergoing stent implantation for significant CAD.

Brief summary: The investigators assessed the hypothesis that whether RH-PAT index (RHI) as a marker of endothelial dysfunction could predict occurrence of ISR after percutaneous coronary intervention (PCI).

Detailed description: This is a prospective observational study of all consecutive patients with coronary artery disease (CAD) treated with PCI at Kumamoto University Hospital between January 2010 and September 2012. Inclusion criteria consisted of patients who were symptomatic for myocardial ischemia and who were undergoing stent implantation for significant CAD.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria consisted of patients who were symptomatic for myocardial ischemia and who were undergoing stent implantation for significant CAD.

Exclusion Criteria:

* Exclusion criteria were balloon angioplasty only without stent deployment, death during hospitalization, and patients who had comorbidities affected RH-PAT results such as hemodialysis, advanced cancer, after surgery of breast cancer, dementia, collagen disease, and not performing RH-PAT with uncertain reason.

Primary outcomes:
measure: Presence or absence of in-stent restenosis
timeFrame: within 1 year
Secondary outcomes:
measure: Endothelial Function
timeFrame: within 1 year
Other outcomes:
Locations:
city: Kumamoto
country: Japan
facility: Kumamoto University
Study officials:
affiliation: Kumamoto University
name: Hisao Ogawa, MD, PhD
role: STUDY_CHAIR
References:
citation: Komura N, Tsujita K, Yamanaga K, Sakamoto K, Kaikita K, Hokimoto S, Iwashita S, Miyazaki T, Akasaka T, Arima Y, Yamamoto E, Izumiya Y, Yamamuro M, Kojima S, Tayama S, Sugiyama S, Matsui K, Nakamura S, Hibi K, Kimura K, Umemura S, Ogawa H. Impaired Peripheral Endothelial Function Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis. J Am Heart Assoc. 2016 Jun 17;5(6):e003202. doi: 10.1161/JAHA.116.003202.